Thierry Conroy, MD; Florence Castan, MSc; Anthony Lopez, MD; et al.
free access
JAMA Oncol. 2022;8(11):1571-1578. doi:10.1001/jamaoncol.2022.3829
This randomized clinical trial examines 5-year outcomes and prognostic factors for overall survival for treatment with modified FOLFIRINOX for patients with pancreatic ductal adenocarcinoma.
Per E. Lønning, MD, PhD; Oleksii Nikolaienko, PhD; Kathy Pan, MD; et al.
open access
JAMA Oncol. 2022;8(11):1579-1587. doi:10.1001/jamaoncol.2022.3846
This case-control study examines the potential association between white blood cell BRCA1 promoter methylation and subsequent risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.
Allen S. Ho, MD; Sungjin Kim, MS; Cynthia Zalt, MPH; et al.
free access
JAMA Oncol. 2022;8(11):1588-1596. doi:10.1001/jamaoncol.2022.3875
This prospective clinical trial examines if expanded size/growth parameters for patients with low-risk thyroid cancer are viable.
-
Invited Commentary
Pushing the Envelope for Active Surveillance
Andrea L. Merrill, MD; Priya H. Dedhia, MD, PhD
JAMA Oncol
Brittany L. Bychkovsky, MD, MSc; Nihat B. Agaoglu, MD, PhD; Carolyn Horton, MS; et al.
open access
JAMA Oncol. 2022;8(11):1598-1606. doi:10.1001/jamaoncol.2022.4071
This retrospective cohort study examines the association of different CHEK2 pathogenic variants with different cancer phenotypes.
Wei-Zhong Jiang, MD; Jian-Min Xu, MD; Jia-Di Xing, MD; et al.
open access
JAMA Oncol. 2022;8(11):1607-1615. doi:10.1001/jamaoncol.2022.4079
This randomized clinical trial compares the short-term efficacy of laparoscopic surgery vs open surgery for treatment of low rectal cancer.
Daniel R. Richardson, MD, MSc; P. Christopher Parish, BS; Xianming Tan, PhD; et al.
free access
JAMA Oncol. 2022;8(11):1616-1623. doi:10.1001/jamaoncol.2022.4194
This cohort study describes the association of variation in QTc formula selection with adverse event grading and chemotherapy delivery in patients with cancer.
-
Editorial
Keeping the Heartbeat Off-Target in Cancer Therapy
Benjamin N. Starobin, MD; Kevin F. Kwaku, MD, PhD
JAMA Oncol
Kyung Hwan Kim, MD, PhD; Jaewon Oh, MD, PhD; Gowoon Yang, MD; et al.
free access
JAMA Oncol. 2022;8(11):1624-1634. doi:10.1001/jamaoncol.2022.4202
This cohort study describes the incidence of atrial fibrillation in patients with lung cancer and assesses predictive cardiac dosimetric parameters.
-
Editorial
Keeping the Heartbeat Off-Target in Cancer Therapy
Benjamin N. Starobin, MD; Kevin F. Kwaku, MD, PhD
JAMA Oncol
Abdulhadi Jfri, MSc, MD; Rachel Meltzer, MPH, MD; Arash Mostaghimi, MPH, MD; et al.
free access
JAMA Oncol. 2022;8(11):1635-1643. doi:10.1001/jamaoncol.2022.4327
This systematic review with meta-analysis examines the incidence of phosphoinositide 3-kinase inhibitor鈥揳ssociated cutaneous adverse events in patients with cancer.
Robert Olson, MD; Will Jiang, MD; Mitchell Liu, MD; et al.
free access
JAMA Oncol. 2022;8(11):1644-1650. doi:10.1001/jamaoncol.2022.4394
This nonrandomized clinical trial examines toxic effects of treatment with stereotactic ablative radiotherapy in a large cohort from a Canadian population-based, provincial cancer program.